Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498290 | 0.87 | CA1 (0.38) | CA12CA2CA9ALDH1A1MAPK1 | |
| SCHEMBL8459820 | 0.84 | CA12 (0.32) | CA12CA2CA9TSHRMAPK1 | |
| SCHEMBL20257609 | 0.83 | CHRM2 (0.32) | CA12CA2CA9CHRM2CHRM4 | |
| SCHEMBL12656337 | 0.82 | FDPS (0.35) | CA12CA2CA9ALDH1A1TSHR | |
| SCHEMBL498168 | 0.81 | CHRM1 (0.36) | ALDH1A1LMNAMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL497808 | 0.81 | CA12 (0.36) | CA12CA2CA9ALDH1A1TSHR | |
| SCHEMBL14065632 | 0.81 | CHRM2 (0.37) | ALDH1A1LMNAMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL497598 | 0.80 | CA12 (0.32) | CA12CA2CA9TSHRMAPK1 | |
| SCHEMBL2825332 | 0.80 | CA2 (0.33) | CA12CA2CA9TSHRMAPK1 | |
| SCHEMBL8059768 | 0.80 | CA12 (0.32) | CA12CA2CA9ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160089341-A1 | METHODS FOR TREATING AND PREVENTING STATUS EPILEPTICUS AND ORGANOPHOSPHATE POISONING | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2016-03-31 | — | — | US | claimed |
| WO-2014107794-A1 | FORMULATIONS AND METHODS FOR THEIR USE IN TREATMENT OF NEUROPATHOLOGY AND NEURODEGENERATION AS A RESULT OF TRAUMATIC INJURY | SAPNA LIFE SCIENCES CORP. (CA) | 2014-07-17 | — | — | WO | claimed |
| WO-2014108808-A2 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF TRAUMA-INDUCED NEUROPATHOLOGY AND NEURODEGENERATION | HENRY JAMES LORNE (CA) | 2014-07-17 | — | — | WO | claimed |
| US-20140193523-A1 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF TRAUMA-INDUCED NEUROPATHOLOGY AND NEURODEGENERATION | SAPNA LIFE SCIENCES CORPORATION (CA) | 2014-07-10 | — | — | US | claimed |
| US-20140194394-A1 | TWO-COMPONENT FORMULATIONS, METHODS AND PROCEDURES TO PREVENT OR REDUCE TRAUMA-INDUCED NEUROPATHOLOGY AND NEURODEGENERATION | SAPNA LIFE SCIENCES CORPORATION (CA) | 2014-07-10 | — | — | US | claimed |
| US-11357793-B2 | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration | SAPNA LIFE SCIENCES CORPORATION (CA) | 2022-06-14 | — | — | US | disclosed |
| US-20210379704-A1 | COMPOSITIONS BASED ON YTTRIUM, CERIUM AND AN ORGANIC COMPOUND, AND STOP-OFF USE THEREOF | RHODIA OPERATIONS (FR) | 2021-12-09 | — | — | US | disclosed |
| US-20190125789-A1 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF TRAUMA-INDUCED NEUROPATHOLOGY AND NEURODEGENERATION | SAPNA LIFE SCIENCES CORPORATION (CA) | 2019-05-02 | — | — | US | disclosed |
| US-20190125701-A1 | Compositions and Methods for Treating Viral Infection in Mammals | UNIV YALE (US) | 2019-05-02 | — | — | US | disclosed |
| EP-3452172-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION IN MAMMALS | Yale University (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10201569-B2 | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration | SAPNA LIFE SCIENCES CORPORATION (CA) | 2019-02-12 | — | — | US | disclosed |
| WO-2017192799-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION IN MAMMALS | YALE UNIVERSITY (US) | 2017-11-09 | — | — | WO | disclosed |
| EP-1272476-A1 | 2-PHENYL-2H-PYRIDAZINE-3-ONES | BASF AKTIENGESELLSCHAFT (DE) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001079183-A1 | 2-PHENYL-2H-PYRIDAZINE-3-ONES | BASF AKTIENGESELLSCHAFT (DE) | 2001-10-25 | — | — | WO | disclosed |
| US-6165944-A | 4-(3-heterocyclyl-1-benzoyl) pyrazoles and their use as herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2000-12-26 | — | — | US | disclosed |
| EP-0777658-B1 | SUBSTITUTED TRIAZOLINONES AS PLANT PROTECTIVE AGENTS | BASF AG (DE) | 1999-12-15 | — | — | EP | disclosed |
| EP-0958292-A1 | 4-(3-HETEROCYCLYL-1-BENZOYL)PYRAZOLES AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-24 | — | — | EP | disclosed |
| US-5885934-A | HERBICIDES OR FOR THE DESICCATION/DEFOLIATION OF PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 1999-03-23 | — | — | US | disclosed |
| WO-1998031682-A1 | 4-(3-HETEROCYCLYL-1-BENZOYL)PYRAZOLES AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-07-23 | — | — | WO | disclosed |
| WO-1996005179-A1 | SUBSTITUTED TRIAZOLINONES AS PLANT PROTECTIVE AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125701-A1 | Compositions and Methods for Treating Viral Infection in Mammals | RPL35, PIGS, HAVCR2 | CA12 234/4885CA2 718/4885CA9 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.